Evotec's Beat Is Real, but the Profit Still Isn't — and Berenberg Won't Budge

Evotec shares picked up 2.5% in the previous session, yet the gain says little about whether the company's underlying business is actually improving. The more telling signal came on 16 October, when Berenberg called the preliminary quarterly figures "surprisingly strong" and left its rating at "Hold" — a pairing that captures the central tension facing investors ahead of the full results on 5 November.

The distinction matters: beating expectations and running a profitable business are two different yardsticks, and Evotec currently satisfies only one of them.

What the Nine-Month Numbers Actually Show

Roughly a week before the Berenberg note, Evotec reported preliminary figures for the first nine months of 2026. Group revenue came in at around EUR 465.0 million, with adjusted EBITDA of roughly EUR ?42.8 million. Both topped market consensus.

The company, however, attributed the positive deviation largely to the timing of consensus estimates. That caveat carries weight. If expectations were spread differently across the year than the actual business trajectory, an interim result can land above forecasts without the outlook for the full year improving at all. Evotec's own explanation for the beat is therefore as important to the investment case as the beat itself.

The Confirmed Guidance Is the Firmer Anchor

For the full year 2026, Evotec reaffirmed group revenue of around EUR 570–610 million. At constant exchange rates, the range sits at EUR 595–635 million. No upgrade accompanied the preliminary numbers.

On adjusted EBITDA, the company continues to guide toward roughly EUR ?70 to ?105 million, or EUR ?60 to EUR ?90 million at constant currencies. Either way, the outlook still envisions an adjusted operating loss.

That does not invalidate the stronger interim showing — it simply caps what investors can reasonably conclude from it. Better than expected means better than expected, not already profitable. Anyone reading a full re-rating into the nine-month figures is running ahead of what management has actually confirmed.

A Hold That Isn't a Contradiction

According to media reports, Berenberg analyst Christian Ehmann kept his price target at EUR 3.60 on 16 October. His positive read on the preliminary results and the unchanged Hold recommendation fit together comfortably: a surprisingly strong interim report can deserve credit while a confirmed full-year framework still justifies restraint.

That separation is more useful than trying to convert every positive number into a clear-cut market signal. The confirmed guidance describes the frame the company still considers achievable — and it remains the more reliable reference point than the word "exceeded."

Holbrook Takes the Science Helm

Alongside the financial picture, a confirmed personnel move is approaching. Joanna Holbrook is set to become Chief Scientific Officer and join the management board on 1 November, with Evotec announcing the appointment on 15 October. Holbrook joins from Novo Nordisk and, according to the company, brings more than 25 years of experience across pharma, biotechnology and science.

Her arrival is a supporting factor for a positive assessment, not a substitute for operational progress. The start date and the subsequent earnings release fall close together, but no near-term financial effect can be inferred from that proximity. The appointment concerns future scientific leadership; the numbers will have to stand on their own.

What 5 November Has to Deliver

The full results for the third quarter and the first nine months of 2026 land on 5 November, and the benchmark is already set. The key question is not whether the positive headline figures get repeated, but how convincingly they are squared with an unchanged annual outlook.

A best-case outcome would be a complete report that places the favourable interim data in a comprehensible context and strengthens confidence in the confirmed guidance — no upgrade required. A convincing explanation of the year-to-date trajectory alone could reduce uncertainty about what the beat actually signifies.

The downside scenario is that the full figures mainly confirm the timing shift against expectations. In that case, the positive surprise would reflect the distribution of forecasts rather than additional earnings power, and the still-guided operating loss would remain the decisive financial counterweight. Treating the beat as a trend change would then look premature — as would reading Holbrook's arrival as a short-term boost to the financials.